Cargando...

Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer

Sorafenib, the first agent developed to target BRAF mutant melanoma, is a multi-kinase inhibitor that was approved by the FDA for therapy of kidney and subsequently liver cancer, and is currently in clinical trials for thyroid, lung and brain cancer. Colorectal cancer with V600E BRAF mutation has sh...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Al-Marrawi, Mhd Yaser, Saroya, Bikramajit Singh, Brennan, Matthew C, Yang, Zhaohai, Dykes, Thomas M, El-Deiry, Wafik S
Formato: Artigo
Lenguaje:Inglês
Publicado: Landes Bioscience 2013
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3841209/
https://ncbi.nlm.nih.gov/pubmed/23792568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.25191
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!